- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00745043
Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study (BOLD)
August 29, 2008 updated by: Waikato Hospital
Do Beta-Blockers Affect the Use of Beta-Agonist Inhalers in COPD?
Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease.
These are very common conditions and many patients have both diseases.
Beta-blocker drugs are extensively used in the treatment of angina, high blood pressure and after heart attacks to decrease symptoms and prolong life.
Beta-agonists are used in COPD to decrease breathlessness and improve exercise tolerance.
It used to be thought that beta-blockers cannot be used in COPD patients as they may make the breathlessness worse, but it has now been established that they can be used safely.
Beta-blocker drugs and beta-agonists have 'opposite' effects on the body and the investigators do not know if they can work together or if they would cancel each other out.
The investigators also do not know which of the different types of beta-blockers now available are better for COPD patients.
This study will investigate what happens to the airways of people taking both of these drugs.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
11
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Waikato
-
Hamilton, Waikato, New Zealand, 3204
- Department of respiratory medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of COPD
- > 40 years of age
- > 15 pack year smoking history
Exclusion Criteria:
- Contra-indication to beta-blocker use
- Severe COPD FEV1 < 30% or 1 L
- Not responsive the methacholine
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: R302
Daily placebo capsules
|
|
ACTIVE_COMPARATOR: R303
Daily metoprolol 95mg capsules
|
|
ACTIVE_COMPARATOR: R304
Daily propranolol 80mg capsules
|
|
ACTIVE_COMPARATOR: Open Label
Daily Metoprolol 190mg capsules
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bronchodilator response to salbutamol after beta-blockers
Time Frame: 7-10 days
|
7-10 days
|
Incremental Shuttle Walk Test Result after taking beta-blockers
Time Frame: 7-10 days
|
7-10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: Bob Hancox, MD FRACP, Waikato Hospital Research Unit
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2005
Primary Completion (ACTUAL)
August 1, 2007
Study Completion (ACTUAL)
August 1, 2007
Study Registration Dates
First Submitted
August 29, 2008
First Submitted That Met QC Criteria
August 29, 2008
First Posted (ESTIMATE)
September 1, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
September 1, 2008
Last Update Submitted That Met QC Criteria
August 29, 2008
Last Verified
August 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NTX/05/04/035
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
University Hospital, GhentGlaxoSmithKline; University GhentCompletedChronic Obstructive Pulmonary Disease (COPD)Belgium
-
Optimum Patient CareRespiratory Effectiveness Group; Boehringer Ingelheim Pharmaceutical Company... and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (13645005)United States
-
Poitiers University HospitalCompletedBroncho Chronic Obstructive Pulmonary DiseaseFrance
Clinical Trials on bronchodilator response
-
The Hospital for Sick ChildrenCompletedCongenital Diaphragmatic HerniaCanada
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Completed
-
University of South-Eastern NorwayCompleted
-
AdventHealthCompletedPain | Pancreatic CancerUnited States
-
Sun Yat-sen UniversityCompletedPrimary Biliary CirrhosisChina
-
Yale UniversityNational Institute of Neurological Disorders and Stroke (NINDS)CompletedAutism Spectrum DisordersUnited States
-
Kansas State UniversityUnited Sorghum Checkoff ProgramCompletedBlood Glucose
-
Centre Hospitalier Universitaire Saint PierreUniversité Libre de BruxellesCompletedHypoxia | Hypercapnia | Hyperventilation SyndromeBelgium
-
University Hospital, MontpellierDirection Générale de l'Offre de SoinsNot yet recruitingChild, Only | Community-acquired PneumoniaFrance
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)RecruitingAutism Spectrum Disorder | AutismUnited States